Business Wire
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
📈
AI Sentiment
Highly Positive
8/10
Latest updates and market news for AGEN
AI Sentiment
Highly Positive
8/10
Share this news page